Mexico - North America Alzheimers Disease Diagnostics Market Size & Outlook
- Clinical Diagnostics
- In Vitro Diagnostics
- Alzheimers Disease Diagnostics Market Outlook
- In Vitro Diagnostics
Global Market
Related Markets
Ask a question about the alzheimers disease diagnostics market
Mexico alzheimers disease diagnostics market highlights
- The Mexico alzheimers disease diagnostics market generated a revenue of USD 149.0 million in 2025 and is expected to reach USD 334.0 million by 2033.
- The Mexico market is expected to grow at a CAGR of 10.7% from 2026 to 2033.
- In terms of segment, imaging techniques was the largest revenue generating diagnostic technique in 2025.
- Biomarkers is the most lucrative diagnostic technique segment registering the fastest growth during the forecast period.
Alzheimers disease diagnostics market data book summary
| Market revenue in 2025 | USD 149.0 million |
| Market revenue in 2033 | USD 334.0 million |
| Growth rate | 10.7% (CAGR from 2026 to 2033) |
| Largest segment | Imaging techniques |
| Fastest growing segment | Biomarkers |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests |
| Key market players worldwide | Quest Diagnostics Inc, Sysmex Corp, Lantheus Holdings Inc, Siemens Healthineers AG ADR, F. Hoffmann-La Roche Ltd., Quanterix, Fujirebio Diagnostics, C2N Diagnostics |
Other key industry trends
- In terms of revenue, Mexico accounted for 1.6% of the global alzheimers disease diagnostics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. alzheimers disease diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- Canada is the fastest growing regional market in North America and is projected to reach USD 871.0 million by 2033.
The increasing awareness about public health and early diagnosis, demographic shifts, and governmental support are driving the market in Mexico. For instance, according to an article published by Eisai Inc, in December 2024, it is estimated that 1.3 million people in Mexico have Alzheimer's disease, which makes up 60–70% of all dementia diagnoses.
People over 65 are most typically affected by Alzheimer's disease. Moreover, strategic initiatives by key market players such as product approval, partnership, and others help in strengthening the market growth. For instance, in December 2024, COFEPRIS approved LEQEMBI, a humanized monoclonal antibody developed by Eisai and Biogen, for the treatment of early-stage AD.
LEQEMBI targets and reduces amyloid-beta protofibrils and plaques in the brain, which are key contributors to AD progression. This approval was based on positive results from the global Phase 3 Clarity AD study, marking a significant advancement in AD treatment options in Mexico.
No credit card required*
Publish Date: Dec 17, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Alzheimers Disease Diagnostics Market Scope
Alzheimers Disease Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Siemens Healthineers AG ADR | View profile | 71,400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | www.siemens-healthineers.com |
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Sysmex Corp | View profile | 10,448 | 1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, Japan, 6510073 | www.sysmex.co.jp |
| Lantheus Holdings Inc | View profile | 834 | 201 Burlington Road, South Building, Bedford, MA, United States, 01730 | www.lantheus.com |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| C2N Diagnostics | View profile | 11-50 | Saint Louis, Missouri, United States, North America | c2n.com/ |
| Fujirebio Diagnostics | View profile | 5001-10000 | Malvern, Pennsylvania, United States, North America | www.fdi.com/ |
| Quanterix | View profile | 251-500 | Billerica, Massachusetts, United States, North America | www.quanterix.com |
Mexico - North America Alzheimers Disease Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Alzheimers Disease Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Imaging Techniques was the largest segment with a revenue share of 44.56% in 2025.
Horizon Databook has segmented the Mexico - North America alzheimers disease diagnostics market based on biomarkers, imaging techniques, genetic testing, cognitive assessment tests covering the revenue growth of each sub-segment from 2021 to 2033.
The increasing awareness about public health and early diagnosis, demographic shifts, and governmental support are driving the market in Mexico. For instance, according to an article published by Eisai Inc, in December 2024, it is estimated that 1.3 million people in Mexico have Alzheimer's disease, which makes up 60–70% of all dementia diagnoses.
People over 65 are most typically affected by Alzheimer's disease. Moreover, strategic initiatives by key market players such as product approval, partnership, and others help in strengthening the market growth. For instance, in December 2024, COFEPRIS approved LEQEMBI, a humanized monoclonal antibody developed by Eisai and Biogen, for the treatment of early-stage AD.
LEQEMBI targets and reduces amyloid-beta protofibrils and plaques in the brain, which are key contributors to AD progression. This approval was based on positive results from the global Phase 3 Clarity AD study, marking a significant advancement in AD treatment options in Mexico.
- Mexico - North America Alzheimers Disease Diagnostics Market Diagnostic Technique Outlook (Revenue, USD Million , 2021-2033)
- Biomarkers
- Imaging Techniques
- Genetic Testing
- Cognitive Assessment Tests
- Mexico - North America Alzheimers Disease Diagnostics Market Type Outlook (Revenue, USD Million , 2021-2033)
- Triage
- Diagnosis
- Screening
- Mexico - North America Alzheimers Disease Diagnostics Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutes
Reasons to subscribe to Alzheimers Disease Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Alzheimers Disease Diagnostics Market Outlook databook
- Our clientele includes a mix of Alzheimers Disease Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico - North America Alzheimers Disease Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Mexico - North America Alzheimers Disease Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Mexico - North America Alzheimers Disease Diagnostics Market, 2021-2033 (US$M)
Mexico alzheimers disease diagnostics market statistics, by diagnostic technique, 2021-2033 (US$M)
